AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01056822
Drug: 2
RxNorm normalized name: I2
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
Trial: NCT04505774
Drug: Crizanlizumab Injection
RxNorm normalized name: crizanlizumab Injection
DrugBank: Crizanlizumab (DB15271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: crizanlizumab injection
Trial: NCT04505774
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sglt2 inhibitor
Trial: NCT01423500
Drug: VP16
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
Trial: NCT01423500
Drug: Fludarabine, OKT3, Treosulfan, Thiotepa
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
Trial: NCT00033332
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00033332
Drug: pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00033332
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03157167
Drug: Tc99m-tilmanocept
RxNorm normalized name: technetium (99mTc) tilmanocept
DrugBank: Tilmanocept (DB15373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Trial: NCT00300417
Drug: VRC-WNVDNA020-00-VP
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00079469
Drug: bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00762164
Drug: Vytorin
RxNorm normalized name: Vytorin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vytorin 10/80 split into 4
Trial: NCT01269203
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg per day
Trial: NCT02405689
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02405689
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03458468
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g Tranexamic acid prior to skin incision
Trial: NCT02192580
Drug: Omega-3
RxNorm normalized name: Omega-3
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
Trial: NCT00412334
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200-1600mg/day po
Trial: NCT00412334
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000-1200mg/day po
Trial: NCT00412334
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 360 micrograms sc weekly
Trial: NCT00412334
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms sc twice weekly
Trial: NCT03458468
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equivalent volume of saline prior to skin incision
Trial: NCT02234882
Drug: BMS-663068
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03733717
Drug: Isatuximab SAR650984
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous
Trial: NCT00979940
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg po given one time before PCI in cath lab.
Trial: NCT00937937
Drug: Dinaciclib
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03054896
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
Trial: NCT00837369
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400ug IV bolus injection, single dosage
Trial: NCT01276600
Drug: Emtricitabine/tenofovir
RxNorm normalized name: EMTRICITABINE/TENOFOVIR
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg of emtricitabine 300mg of tenofovir
Trial: NCT03563716
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
Trial: NCT03481400
Drug: Calcitonin Gene-Related Peptide
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
Trial: NCT03563716
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Trial: NCT04521478
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1358894
Trial: NCT04521478
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine
Trial: NCT02829060
Drug: Nitrofurantoin 100 MG, 7d
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 day course, 100 mg twice daily, PO
Trial: NCT02829060
Drug: Ampicillin 2g
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peri-operative dose: 2 grams, IV
Trial: NCT02829060
Drug: Nitrofurantoin 100 mg, 48 hrs
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 hour course, 100 mg twice daily, PO
Trial: NCT04300231
Drug: epidural bupivacaine 0.05%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
Trial: NCT04300231
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml
Trial: NCT04300231
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mL
Trial: NCT04300231
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mL
Trial: NCT04300231
Drug: /hydromorphone 0.05mg/ml
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
Trial: NCT02926859
Drug: Cannabidiol as add-on
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
Trial: NCT02340676
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
Trial: NCT02485834
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2/day IV
Trial: NCT02485834
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 IV
Trial: NCT02485834
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m\^2 IV
Trial: NCT03697564
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 IV on days 1, 8, and 15 Q4W
Trial: NCT03697564
Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480mg IV on Day 1 Q4W
Trial: NCT03697564
Drug: Cabiralizumab
RxNorm normalized name: Cabiralizumab
DrugBank: Cabiralizumab (DB15082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg/kg IV on day 1 and 15 Q4W
Trial: NCT03969446
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03969446
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00742612
Drug: Placebo (normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
Trial: NCT00006394
Drug: growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668784
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03745326
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.
Trial: NCT03745326
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
Trial: NCT03139305
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
Trial: NCT03139305
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High dose intravenous infusion for 72 hours at 25 ng/kg/min
Trial: NCT03533283
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
Trial: NCT03533283
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
Trial: NCT03533283
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
Trial: NCT03533283
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Trial: NCT03533283
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
Trial: NCT03533283
Drug: 89Zr-Df-IAB22M2C
RxNorm normalized name: Zirconium zr 89-df-iab22m2c
DrugBank: Zirconium (89Zr) crefmirlimab berdoxam (DB19157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
Trial: NCT04046445
Drug: BI 754091
RxNorm normalized name: Anti-pd-1 monoclonal antibody bi 754091
DrugBank: Ezabenlimab (DB17483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥ 7 IV infusions
Trial: NCT04046445
Drug: VSV-GP128
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
DrugBank: Ebola Zaire vaccine (live, attenuated) (DB15595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single IV injection
Trial: NCT03263026
Drug: Enzastaurin Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP + Enzastaurin (Kinenza®) 125 mg
Trial: NCT00448240
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
Trial: NCT03522246
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral rucaparib will be administered twice daily
Trial: NCT03522246
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV nivolumab will be administered once every 4 weeks
Trial: NCT04032964
Drug: L19TNF
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
Trial: NCT01391962
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
Trial: NCT01391962
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
Trial: NCT01391962
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg daily for prophylaxis of thrombosis.
Trial: NCT03879512
Drug: depletion of regulatory T cells
RxNorm normalized name: Autologous CD4+CD25hiFoxP3+regulatory T cells
DrugBank: Autologous CD4+CD25hiFoxP3+regulatory T cells (DB18655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral metronomic cyclophosphamide
Trial: NCT00392327
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00392327
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00392327
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00392327
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01404819
Drug: Anesthesia with Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergo anesthesia with xenon (remifentanil with xenon).
Trial: NCT04500587
Drug: ZN-d5
RxNorm normalized name: VITAMIN D5
DrugBank: 1alpha-Hydroxyvitamin D5 (DB13097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agent; 25 mg or 100 mg formulation
Trial: NCT03571438
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment of cell culture with Sunitinib
Trial: NCT03571438
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment of cell culture with Pazopanib
Trial: NCT03571438
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment of cell culture with Temsirolimus
Trial: NCT02338674
Drug: Tenofovir and telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tenofovir and telbivudine administered at least 48 weeks
Trial: NCT02338674
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tenofovir administered at least 48 weeks
Trial: NCT02525757
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
Trial: NCT02525757
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
Trial: NCT02546986
Drug: CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
Trial: NCT02546986
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
Trial: NCT03944434
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ribociclib 600 mg/day orally
Trial: NCT00474812
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01506596
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
Trial: NCT03816696
Drug: DTG
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
Trial: NCT04030169
Drug: Midomafetamine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
Trial: NCT02661893
Drug: JNJ-42847922
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
Trial: NCT02661893
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
Trial: NCT03743636
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.